Oral Care With 3% Hydrogen Peroxide (Oroxid®) in ICU - Effects on the Lower Airway Microbial Colonisation

Launched by CHARLES UNIVERSITY, CZECH REPUBLIC · Sep 19, 2023

Keywords

ClinConnect Summary

This clinical trial, called HyPerMICROBE, is investigating the effects of daily oral care using a 3% hydrogen peroxide solution (Oroxid®) compared to standard care (0.2% chlorhexidine) for patients in the Intensive Care Unit (ICU) who are on mechanical ventilation. The goal is to see if using hydrogen peroxide can help reduce the growth of harmful bacteria in the lungs, which can lead to a serious condition known as ventilator-associated pneumonia (VAP).

To participate in this trial, individuals must be at least 18 years old, expected to stay in the ICU for more than five days, and need mechanical ventilation for at least 72 hours. Participants will be closely monitored, and those who qualify will receive either the hydrogen peroxide treatment or the standard care as part of their daily oral hygiene routine. This trial aims to find out if the new treatment is more effective in preventing infections compared to the usual method. It's important to note that some patients may not be eligible, especially those with certain medical conditions or who are pregnant.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥18 years
• • 2. In-patient of ICU and expected to stay \> 5 days
• • 3. Mechanical ventilation or imminent need of it; predicted length of mechanical ventilation (MV) ≥ 72h
• • 4. Clinical Pulmonary Infection score (CPIS) less than 6 at the baseline
• • 5. No history and symptoms of aspiration at the baseline
• Exclusion Criteria:
• • 1. ATB therapy of respiratory infection on admission
• • 2. Suspected pulmonary infection on admission and in the first 48h of mechanical ventilation
• • 3. Pregnancy
• • 4. Oral ulcers or injuries
• • 5. Patient with a history of hydrogen peroxide allergy